CAR-T
-
FDA to adjust CAR-T cell therapy for secondary cancer black box warning
In light of the latest developments, the U.S. Food and Drug Administration (FDA) is planning to revise the secondary malignancy risk warning for CAR-T cell therapy based on the latest safety data. At
View
